Transgene S.A.
0OCQ.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$194.78M
Close$
$0.01
99.2% downside
Current Fair Value
99.2% downsideOvervalued by 99.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $194.78 Million |
|---|---|
| Enterprise Value | $193.02 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.26 |
| Beta | 0.69 |
| Outstanding Shares | 274,373,691 |
Return
| Return on Equity | -64.71% |
|---|---|
| Return on Assets | -56.74% |
| Return on Invested Capital | -60.84% |
Valuation & Multiples
| P/E Ratio | -4.19 |
|---|---|
| PEG | 21.57 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 279.41 |
| Enterprise Value to EBIT | -2.79 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Transgene S.A.
156 employees
CEO: Alessandro Riva Transgene SA is a biotechnology company focused on the research and development of therapeutic vaccines and oncolytic viruses, with a primary objective to treat cancer and infectious diseases. Its product pipeline includes TG4050, a ther...